Fed. Circ. Resurrects Hindsight Bias In Post-KSR World

Law360, New York (August 23, 2017, 1:36 PM EDT) -- In Millennium Pharmaceuticals Inc. v. Sandoz Inc., 862 F.3d 1356 (Fed. Cir. 2017), Federal Circuit Judges Pauline Newman, Haldane Mayer and Kathleen O’Malley overturned a district court’s invalidation of a pharmaceutical patent. The Federal Circuit reversed a district court’s holdings of obviousness and inherency regarding a pharmaceutical compound, using hindsight arguments explicitly rejected in KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398 (2007).

The disputed compound is sold as a cancer treatment named Velcade. Its precursor bortezomib is a proteosome inhibitor with known stability problems. After failing to develop a suitable liquid formulation, researchers made an alternate form by lyophilizing...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS